2026/04/14 by E. F. Vasconcelos, Felipe de Menezes Cunha, Gustavo Mesquita de Oliveira +3 · 1 voice
Medicine · #Acute Myeloid Leukemia Research #Chronic Myeloid Leukemia Treatments #Multiple Myeloma Research and Treatments
paper · pdf · doi:10.46765/2675-374x.2025v7n1e318
openalex publication_date 2026/04/14 · openalex created_date 2026/04/15 · openalex updated_date 2026/06/26
Chronic myelomonocytic leukemia (CMML) represents a diagnostic and therapeutic challenge in the Brazilian public healthcare system, particularly due to limited access to advanced diagnostic tools and disease-modifying therapies. A retrospective chart review was conducted, including patients diagnosed with CMML from 2015 to 2025 at a university hospital in northeastern Brazil. Fourteen patients were identified, with a mean age of 58.7 years, and 50% were male. At diagnosis, 57.1% were in the chronic phase and 42.9% in the acute phase. Only two patients (14.3%) received hypomethylating agents, and four (28.6%) underwent allogeneic hematopoietic stem-cell transplantation. The median overall survival for the cohort was 25 months. Patients diagnosed in the acute phase had a shorter median overall survival compared to those diagnosed in the chronic phase (8 vs. 25 months). A trend toward improved survival was observed among transplanted patients (25 vs. 8 months). Compared with contemporary data, patients in this cohort had lower exposure to hypomethylating therapy, although transplant-related characteristics and early engraftment outcomes were similar. Structural and therapeutic limitations within the public healthcare system may impact disease management and outcomes, reinforcing the importance of improving access to diagnostic resources, disease-modifying therapies, and timely referral for transplantation.